Clinical Scorecard: Nationwide Swedish Study on Childhood-onset Inflammatory Bowel Disease and Its Association with Chronic Non-bacterial Osteomyelitis from 2002 to 2022
At a Glance
Category
Detail
Condition
Childhood-onset inflammatory bowel disease (IBD) and chronic non-bacterial osteomyelitis (CNO)
Key Mechanisms
IBD is a gastrointestinal disorder with extraintestinal inflammatory manifestations; CNO is an aseptic inflammatory bone disorder often co-occurring with immune-mediated diseases including IBD
Target Population
Children diagnosed with IBD before 18 years of age in Sweden
Care Setting
Pediatric gastroenterology within the Swedish public healthcare system
Key Highlights
Children with IBD have a six-fold increased risk of developing CNO compared to non-IBD matched comparators.
IBD patients with CNO are younger at IBD diagnosis (median 11 vs 14 years) and have more frequent extraintestinal manifestations (62% vs 21%).
Biologic treatments are more commonly prescribed in IBD patients with CNO (78% vs 44%), addressing both IBD and CNO.
Guideline-Based Recommendations
Diagnosis
Consider CNO diagnosis in children with IBD presenting with bone pain, swelling, or inflammation.
Use imaging modalities such as MRI to detect bone marrow edema, lytic areas, and periosteal reaction characteristic of CNO.
Management
Treat IBD patients with CNO using biologic therapies as indicated for both conditions.
Monitor for extraintestinal manifestations in childhood-onset IBD patients, especially those younger at diagnosis.
Monitoring & Follow-up
Regular clinical assessment for musculoskeletal symptoms in pediatric IBD patients.
Use imaging follow-up to evaluate disease activity and response to treatment in CNO.
Risks
Increased risk of CNO in childhood-onset IBD necessitates vigilance for bone inflammation.
Younger age at IBD onset and presence of extraintestinal manifestations may indicate higher risk for CNO.
Patient & Prescribing Data
Children with childhood-onset IBD, with and without CNO
Higher biologic therapy usage in IBD patients with CNO suggests need for targeted immunomodulatory treatment addressing both intestinal and bone inflammation.
Clinical Best Practices
Early recognition of CNO in children with IBD to initiate appropriate treatment.
Multidisciplinary care involving pediatric gastroenterologists and rheumatologists for managing IBD with CNO.
Use of nationwide health registers can aid in identifying and monitoring rare comorbidities in pediatric IBD.
